Optimize Your Cancer Research

We offer deep product development expertise in all cancer-related indications, including rare cancer and gene studies.

2-6 June, 2023

Booth #24168

Our Oncology Experience

  • More than 190 oncology and hematology clinical studies completed through every phase
  • Expertise in dose-finding studies
  • Proficiency in biomarker-guided design and patient matching
  • Platform experience with novel technologies and next-generation therapeutics
    • Cell therapies / CAR-T
    • RNA therapies
    • Radiopharmaceuticals
    • Cancer Vaccines
    • Oncolytic virus
    • Metabolic pathway inhibitors
    • Growth pathway inhibitors, non-targeted cytotoxic therapeutics

Premier Research Expertise

Cancer Research is Complex. Let's Navigate it. Together.

CAR T-Cell Therapies: Extending Hope with Broadened Access

Read Now

9 Tips for Designing and Operationalizing Early-Stage Precision Oncology Studies

Read Now

Can Your Protocol Flex? The Importance of Adaptive Trial Designs in Precision Oncology Studies

Read Now

The Rise of Radiotherapeutics: Brief History and Best Practices for Clinical Trials

Read Now

Meet our Experts at ASCO

Premier’s oncology and hematology specialists have deep experience in virtually all cancer-related indications, especially rare cancer, one of the largest areas of unmet need.

Brant Nicks

Senior Vice President, Clinical Development

Ayesha A. Pandit, M.D., M.S., MBA

Vice President, Medical Affairs

Rupa Doshi, Ph.D.

Vice President, Oncology Strategy

Ashley Herrick, Ph.D.

Executive Director, Oncology Program Strategy

Faisal Rahman, M.D.

Medical Director

Sandra Bihary-Waltz, DBA(c), MSN, BSN

Senior Vice President, Regulatory Affairs

Charlie Chrisawn

Senior Program Director, Diagnostics

Marina Lewis, MD., PhD

Senior Medical Director III, Oncology/Hematology

Visit Premier Research at Booth #24168 at the ASCO Annual Meeting. Stay up to date on new clinical cancer advances in every area of cancer research, gain real-time insights from world-renowned faculty, and connect with one of the largest, most diverse audiences in global oncology.